The Health Innovation Network Yorkshire & Humber, Nexus (University of Leeds), West Yorkshire Integrated Care Board and ...

Hansa Biopharma A/S has turned in positive data from a pivotal U.S. phase III trial of imlifidase, an enzyme that speedily removes antibodies from the bloodstream, enabling highly sensitized kidney ...

Once-daily oral GLP-1 drug orforglipron leads to significant, dose-dependent weight loss and metabolic benefits without diabetes.

PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...

As a digital nomad living in Cozumel, I've come to know the island very well. Here's all you need to know about living in this piece of paradise.

Small acts of kindness can make a big difference. These people, in very different situations, discovered how much goodness ...

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and ...

In a continued effort to protect the health of people in Canada and the environment, the federal government is taking the next step in addressing per- ...

Main outcome measures The main outcome was the type of injuries observed by international healthcare workers during the ...

Bobcaygeon, ON - What is the Jeep Gladiator?Is it a Wrangler, a pickup truck, or something entirely different?The short ...

GUINNESS gracious, boozers are going crazy for the black stuff – and not just in its home city of Dublin.  Gen Z drinking game Split the G, where you align the letter on your glass with the ...